Adrian Senderowicz, a director at Puma Biotechnology, Inc. (NASDAQ:PBYI), has executed a sale of 27,000 shares of common stock valued at $194,310 on June 12, 2026, according to a Securities and Exchange Commission filing. The transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted on March 12, 2025.
This sale immediately followed the acquisition of 27,000 Restricted Stock Units on June 11, 2026, which were granted at a price of $0 and vest based on service continuation. Following these transactions, Senderowicz holds 27,000 shares directly. The transaction occurs as Puma Biotechnology reports a first-quarter 2026 net loss per share of -$0.04, missing analyst expectations of $0.00, with revenue of $44.8 million falling short of the $49 million forecast, representing an -8.57% revenue surprise. The stock has surged over 104% over the past year, with some analysis suggesting it remains undervalued. No new information regarding potential mergers or acquisitions was included in the earnings release, and analyst firms have not recently provided upgrades or downgrades for Puma Biotech. The company's financial performance remains a key focus for investors assessing future prospects.
Key Points
- Director Transaction: Adrian Senderowicz sold 27,000 shares at prices ranging from $6.98 to $7.32 per share on June 12, 2026, under a Rule 10b5-1 plan adopted on March 12, 2025.
- Recent Share Acquisition: The sale followed the acquisition of 27,000 Restricted Stock Units on June 11, 2026, acquired at $0, vesting on the earlier of the one-year anniversary or the annual shareholder meeting following the grant date, subject to continued service.
- Financial Context: Puma Biotechnology reported a first-quarter 2026 net loss per share of -$0.04, missing expectations of $0.00, with revenue of $44.8 million falling short of the $49 million forecast, representing an -8.57% revenue surprise.
Risks and Uncertainties
- Earnings Performance: The company's first-quarter 2026 earnings missed analyst expectations, with a net loss per share of -$0.04 and revenue of $44.8 million falling short of the $49 million forecast, highlighting challenges in meeting market expectations.
- Valuation and Market Perception: While the stock has surged over 104% in the past year, some analysis suggests it remains undervalued, but the lack of recent analyst upgrades or downgrades and no new information on potential mergers or acquisitions leaves the future valuation trajectory uncertain.